MarketCap
Facebook
X
Telegram
Caladrius Biosciences Langfristiger Schuldenstrom | CLBS
Langfristiger Schuldenstrom Jährlich Caladrius Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 137 K | 168 K | 180 K | 229 K | 370 K | 354 K | - | - | 3.13 M | 4.17 M | 1.11 M | - | - | - | - | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 4.17 M | 137 K | 1.09 M |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
AVROBIO
AVRO
|
889 K | - | 1083.1 % | $ 745 M |  USA |
 |
AstraZeneca PLC
AZN
|
382 M | - | - | $ 96.9 B |  Britain |
 |
Brainstorm Cell Therapeutics
BCLI
|
208 K | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
EyePoint Pharmaceuticals
EYPT
|
2.02 M | $ 0.39 | 9.06 % | $ 28.6 K | USA |
 |
Bio-Path Holdings
BPTH
|
83 K | - | - | $ 100 K | USA |
 |
Cara Therapeutics
CARA
|
116 K | - | -3.03 % | $ 260 M | USA |
 |
ChromaDex Corporation
CDXC
|
1 M | - | -0.88 % | $ 598 M | USA |
 |
Diffusion Pharmaceuticals
DFFN
|
113 K | - | 11.68 % | $ 8.97 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
4 K | - | -5.68 % | $ 8.28 M | USA |
 |
Enochian Biosciences
ENOB
|
294 K | - | - | $ 40.5 M | USA |
 |
Esperion Therapeutics
ESPR
|
2.1 M | - | - | $ 661 M | USA |
 |
Evofem Biosciences
EVFM
|
128 K | - | 7.55 % | $ 38.1 M | USA |
 |
Eyenovia
EYEN
|
512 K | - | 49.81 % | $ 13.2 M | USA |
 |
FibroGen
FGEN
|
12.6 M | - | - | $ 889 M | USA |
 |
Homology Medicines
FIXX
|
693 K | - | 0.77 % | $ 53.4 M | USA |
 |
Amicus Therapeutics
FOLD
|
8.74 M | - | - | $ 4.47 B | USA |
 |
Frequency Therapeutics
FREQ
|
2.67 M | - | - | $ 528 M | USA |
|
Galecto
GLTO
|
15 K | - | - | $ 762 M |  Danmark |
 |
GlycoMimetics
GLYC
|
435 K | - | 9357.83 % | $ 1.01 B | USA |
 |
Graybug Vision
GRAY
|
203 K | - | -11.23 % | $ 9.65 M | USA |
|
Galera Therapeutics
GRTX
|
133 K | - | -32.59 % | $ 7.61 M | USA |
 |
Happiness Biotech Group Limited
HAPP
|
155 K | - | 1.35 % | $ 17.8 M |  China |
 |
Novavax
NVAX
|
9.88 M | $ 10.15 | -6.8 % | $ 1.64 B | USA |
 |
Hepion Pharmaceuticals
HEPA
|
116 K | - | -18.79 % | $ 39.3 K | USA |
 |
Hoth Therapeutics
HOTH
|
5.68 K | - | - | $ 18.8 M | USA |
 |
IMARA
IMRA
|
399 K | - | 15.96 % | $ 663 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
1.62 M | - | - | $ 1.45 B | Britain |
 |
KemPharm
KMPH
|
419 K | - | -0.34 % | $ 200 M | USA |
 |
Kezar Life Sciences
KZR
|
2.33 M | - | - | $ 53.3 M | USA |
 |
Lixte Biotechnology Holdings
LIXT
|
595 K | - | - | $ 63.4 M | USA |
 |
Magenta Therapeutics
MGTA
|
367 K | - | -7.74 % | $ 41.6 M | USA |
 |
NovaBay Pharmaceuticals
NBY
|
422 K | - | - | $ 11.3 M | USA |
 |
NeuroBo Pharmaceuticals
NRBO
|
68 K | - | 0.43 % | $ 12 M | USA |
 |
Opthea Limited
OPT
|
93 K | - | - | $ 1.2 B |  Australia |
 |
Verastem
VSTM
|
535 K | $ 8.74 | 0.52 % | $ 606 M | USA |
|
BiomX
PHGE
|
1.44 M | $ 1.85 | 14.2 % | $ 3.02 M |  Israel |
 |
Pieris Pharmaceuticals
PIRS
|
202 K | - | -15.58 % | $ 1.22 B |  Germany |
 |
Plus Therapeutics
PSTV
|
56 K | - | - | $ 301 M | USA |
 |
Pluristem Therapeutics
PSTI
|
996 K | - | -1.9 % | $ 33.3 M | Israel |
 |
Qualigen Therapeutics
QLGN
|
241 K | - | 5.59 % | $ 1.16 M | USA |
|
Qilian International Holding Group Limited
QLI
|
241 K | - | -6.08 % | $ 184 M | China |
 |
Cassava Sciences
SAVA
|
104 K | - | - | $ 110 M | USA |
 |
Selecta Biosciences
SELB
|
4.15 M | - | -8.69 % | $ 126 M | USA |
 |
Sangamo Therapeutics
SGMO
|
1.7 M | - | - | $ 50.4 M | USA |